ASPIRA WOMEN’S HEALTH: IMPROVING OVARIAN CANCER DETECTION $AWH
Excited to share an article about Aspira Women’s Health Inc (Nasdaq: AWH), a bio-analytical-based women's health company focused on developing gynecologic disease diagnostic tools.
Aspira's total revenue was $8.2 million for FY22, an increase of 20% compared to $6.8 million for FY21. Gross profit margin was 53% for FY22 compared to 45% for FY21.
The Company has a $1B pipeline opportunity for blood tests in ovarian cancer and endometriosis, and the Company is likely to see increased revenue growth due to its one-of-a-kind predictive tests. This makes Aspira an interesting watch.
Read on to know more:
https://www.aviseanalytics.com/aspiras-womens-health-improving-ovarian-cancer-detection/